The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
Medpage Today on MSN4d
Obesity Epidemic Peaked? FDA Reviews Menopause Drug; Metabolic Surgery and CancerA meta-analysis of over 3.7 million adults with obesity found that pancreatic cancer risk was lower for those who underwent ...
FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...
A ruling issued Friday in the U.S. District Court for the Northern District of Texas permits the makers of compounded versions of tirzepatide, the active ingredient in Zepbound and Mounjaro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback